Organization | Dallah Healthcare Company

Dallah Healthcare Company Report issue

Academic/Hospital Phase 2

Founded: Riyadh Saudi Arabia (1994)

Organization Overview

First Clinical Trial

2017

NCT03373149

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2020

Timeline

NOW

Now

Alternative names

Riyadh Fertility and Reproductive Health center

Active Ingredients

Drugs in Phase 2 Trials (8)

cetrorelix (cetrotide) (1 trial)

filgrastim (neupogen) (1 trial)

follitropin alfa (1 trial)

letrozole (femara) (1 trial)

platelet rich plasma (1 trial)

recombinant human choriogonadotropin alfa (Ovidrel) (2 trials)

somatropin (protropin) (1 trial)

triptorelin (Trelstar) (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Infertility (Phase 2)

Infertility, Female (Phase 2)

Overview

Highest Phase: Phase 2
# of Trials: 5
# of Trial APIs: 8